Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
Lists
Only you see this
Abstract
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and statistical reasoning. The plausibility that vaccine protection against symptomatic COVID-19 could be accompanied by a shift toward more SARS-CoV-2 infections that are asymptomatic is highlighted, as well as the potential implications of such a shift.
BibTeX
@article{mehrotra2020clinical,
author = {Devan V. Mehrotra and Holly Janes and Thomas R. Fleming and Paula W. Annunziato and Kathleen M. Neuzil and Lindsay N. Carpp and David Benkeser and Elizabeth R. Brown and Marco Carone and Iksung Cho and Deborah Donnell and Michael P. Fay and Youyi Fong and Shu Han and Ian Hirsch and Ying Huang and Yunda Huang and Ollivier Hyrien and Michal Juraska and Alex Luedtke and Martha Nason and An Vandebosch and Haiyu Zhou and Myron S. Cohen and Lawrence Corey and Jonathan Hartzel and Dean Follmann and Peter B. Gilbert},
title = {{Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials}},
journal = {Annals},
year = {2020},
doi = {10.7326/m20-6169},
}Loading related content...